Alzheimer's Disease (AD) represents a significant public health problem among the elderly with prevalence estimates ranging from 2 to 4 million in the United States and the prevalence of AD among minorities is at least as high as among the predominant Caucasian cultural groups. Yet minority groups who often have greater medical needs are under- represented in clinical studies. The goal of this core is to improve minority participation in clinical trials and thus insure that safety and efficacy of potential treatments is adequately evaluated for these groups.
Our specific aims are as follows. (1) Assist ADCS investigators in developing protocols which permit maximum participation by minority subjects. This work includes identifying and eliminating culturally biased inclusion and exclusion criteria, providing translations of study instruments, and developing strategies for recruiting from minority populations. (2) Support enrollment efforts by providing staff training, and by developing informational materials for community based minority health professionals and lay people. (3) Use data across all trials to maximize our understanding of the safety and efficacy profile of potential treatments for AD in minority populations. The availability of individual subject data and the commonality of data collection tools and staffing across all ADCS trials will maximize the validity of meta- analyses that can be conducted to address questions about therapeutic profiles in minority groups. Further, the combination of subjects in placebo arms of all trials will provide a mechanism to examine ethnically based differences in rates of progression.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AG010483-10S1
Application #
6455758
Study Section
Project Start
2001-06-01
Project End
2001-09-14
Budget Start
Budget End
Support Year
10
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Rockenstein, Edward; Ostroff, Gary; Dikengil, Fusun et al. (2018) Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies. J Neurosci 38:1000-1014
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Chen, Yun-Fei; Ni, Xiao; Fleisher, Adam S et al. (2018) A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement (N Y) 4:46-53
Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535
Moussa, Charbel; Hebron, Michaeline; Huang, Xu et al. (2017) Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation 14:1
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
El-Agnaf, Omar; Overk, Cassia; Rockenstein, Edward et al. (2017) Differential effects of immunotherapy with antibodies targeting ?-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiol Dis 104:85-96
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2017) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord 31:141-145
Kennedy, Richard E; Cutter, Gary R; Wang, Guoqiao et al. (2017) Challenging Assumptions About African American Participation in Alzheimer Disease Trials. Am J Geriatr Psychiatry 25:1150-1159

Showing the most recent 10 out of 294 publications